Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • arkal
    advancing one byte at a time!
    • Jun 2011
    • 56

    Perplexed!

    Ok so this isn't really a problem per-say but i was just curious as to what it really means....

    I ran picsrd's insert size metrics on my PE RNA Seq data (mapped to the Ensembl Transcriptome model) and iin the results i get the size of largest insert as 11kb.....

    does this mean that a read in a pair has mapped to 1 point and its mate has mapped to another gene somewhere else in the consolidated transcriptome reference, 11kb away, or does it means something else altogether?
  • dpryan
    Devon Ryan
    • Jul 2011
    • 3478

    #2
    What makes you think that 11kb would indicate a different gene. I'm not sure how informative the insert size metric would be on RNAseq data, given that it's going to be spliced. 11kb could easily be the next exon. Just as an example, I have single reads that span 15kb, simply because of splicing.
    Last edited by dpryan; 07-30-2012, 04:42 AM.

    Comment

    • arkal
      advancing one byte at a time!
      • Jun 2011
      • 56

      #3
      HEy thanks for your reply! Did you map your RNA Seq data to a trasncriptome reference or to the HG18/19 Human Genome reference?

      I've mapped my data to the Ensembl Transcriptome reference so shouldn't the introns not be present in it at all? So there's no question of it being so far away due to splicing.

      Comment

      • dpryan
        Devon Ryan
        • Jul 2011
        • 3478

        #4
        Generally you would map things to the genome with a splicing aware aligner (tophat2/bowtie2, gsnap, etc.). What makes you think that Ensembl has all of the existing splices for a gene? It's quite possible that you have reads covering splicing events that are unannotated. It's also possible that you just have on read misaligned. It's often helpful to look at the data in IGV or similar to get a better feel for these sorts of things.

        Comment

        • arkal
          advancing one byte at a time!
          • Jun 2011
          • 56

          #5
          You got a point there! It's not 100% only exons and there may be unannotated regions. I hadn't considered that.

          And yeah i'm running tophat now. I ran a BWA of my reads onto the trscpt ref first to see what sort of duplication rate i'm really looking at.

          will check out the alignment on IGV asap!

          Thanx a ton!

          Comment

          Latest Articles

          Collapse

          • SEQadmin2
            Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
            by SEQadmin2


            Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

            The systematic characterization of the human proteome has
            ...
            07-20-2026, 11:48 AM
          • SEQadmin2
            Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
            by SEQadmin2



            Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
            ...
            07-09-2026, 11:10 AM
          • SEQadmin2
            Cancer Drug Resistance: The Lingering Barrier to Rising Survival
            by SEQadmin2



            Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

            There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
            07-08-2026, 05:17 AM

          ad_right_rmr

          Collapse

          News

          Collapse

          Topics Statistics Last Post
          Started by SEQadmin2, 07-24-2026, 12:17 PM
          0 responses
          29 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-23-2026, 11:41 AM
          0 responses
          21 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-20-2026, 11:10 AM
          0 responses
          212 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-13-2026, 10:26 AM
          0 responses
          78 views
          0 reactions
          Last Post SEQadmin2  
          Working...